BioSpace News Archive

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA) today announced that Thomas Butler, Biomea Fusion’s Chief Executive Officer and Chairman of the Board, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 from 8:15 am – 8:55 am PST.

Dyne Therapeutics, Inc. (Nasdaq: DYN) today announced it plans to report initial clinical data from its Phase 1/2 ACHIEVE and DELIVER trials on January 3, 2024, and to host a virtual event at 8:00 a.m. ET.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 42nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m. Pacific Time on Tuesday January 9, 2024 in San Francisco. Kevin Gorman, Chief Executive Officer, will present at the conference.

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob M. Chacko, M.D., chief executive officer, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 11:15 a.m. PT.